Rigel has an exclusive license and supply agreement with Grifols to develop and commercialize TAVALISSE (fostamatinib) in all potential indications in Europe, Turkey, MENA, Russia and CIS.
TAVLESSE launched in Europe in July 2020 for the treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments.
Rigel received an upfront cash payment, is eligible for regulatory and commercial milestone payments, and receives tiered royalty payments on net sales of TAVALISSE in the territory.